Retrieved from Pediatric Oncall
Following administration in animal models: BPC-157 demonstrates rapid systemic distribution within 15-30 minutes with unusual oral bioavailability TB-500 shows tissue-specific accumulation with preferential uptake in injured areas GHK-Cu exhibits copper-mediated transport and gene-modulating tissue binding KPV utilizes PepT1 transporter-mediated uptake with enhanced delivery to inflamed tissues Combined formulation provides immediate, sustained, and targeted bioactivity across multiple mechanisms Distribution studies suggest that injury sites and inflamed tissues tend to concentrate multiple components through different mechanisms BPC-157 through injury-site targeting, TB-500 through actin-rich repair zones, GHK-Cu through copper-dependent pathways, and KPV through upregulated PepT1 in inflammation, potentially enhancing local therapeutic effects
But I want to sleep well at night. In February, I flew to Charleston and met with Koniver in a modern red brick building that houses his clinic
This is completely normal and is a sign that the active, reduced glutathione is present, as sulfur is a core component of the molecule
The results were consistent: Trunk fat reduction: Tesamorelin-treated patients showed statistically significant reductions in trunk fat versus placebo at 26 weeks.[1] VAT reduction: Using cross-sectional CT imaging, tesamorelin produced approximately 1520% reductions in visceral adipose tissue compared to placebo.[1,2] Triglyceride improvement: Alongside fat reduction, tesamorelin improved triglyceride levels a key marker in metabolic syndrome.[2] Tesamorelin IGF-1 elevation: Treatment reliably elevated IGF-1 levels toward age-appropriate norms, confirming successful GH-axis stimulation.[1] These reductions occurred without dietary caloric restriction being mandated
Some look promising, but we need large, well-designed trials before we can claim prevention
